Ticker Details
XBiotech Inc. Common Stock XBiotech Inc is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases.
IPO Date:	April 13, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$69.51M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.29 | 3.13%
Avg Daily Range (30 D):	$0.03 | 1.23%
Avg Daily Range (90 D):	$0.03 | 1.36%

Institutional Daily Volume
Avg Daily Volume:	.12M
Avg Daily Volume (30 D):	.03M
Avg Daily Volume (90 D):	.03M

Trade Size
Avg Trade Size (Sh.):	128
Avg Trade Size (Sh.) (30 D):	214
Avg Trade Size (Sh.) (90 D):	185

Institutional Trades
Total Institutional Trades:	185
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$1.87M
Avg Institutional Trade (90 D):	$1.87M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.63M
Avg Closing Trade (30 D):	$4.37M
Avg Closing Trade (90 D):	$4.37M
Avg Closing Volume:	245.72K

News

Jun 15, 2026 @ 1:00 PM XBiotech Launches Phase II Clinical Trial Evaluati... Source: Xbiotech Inc.

Jan 14, 2025 @ 9:37 PM Wolf Haldenstein Adler Freeman & Herz LLP announce... Source: Wolf Haldenstein Adler Freeman & Herz Llp

Dec 24, 2024 @ 12:53 AM XBiotech suspend son programme de rhumatologie Source: N/A

Dec 24, 2024 @ 12:53 AM XBiotech setzt Rheumatologieprogramm aus Source: N/A

Aug 23, 2024 @ 3:51 PM Cancer Cachexia Market Forecasted to Reach $3.14 B... Source: Researchandmarkets.Com

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.48	$-.22	$-.18
Diluted EPS
Revenue		$M	$M
Gross Profit
Net Income / Loss	$-45.13M	$-6.73M	$-5.51M
Operating Income / Loss	$-48.22M	$-6.15M	$-6.27M
Cost of Revenue
Net Cash Flow	$-24.84M	$1.41M	$1.13M
PE Ratio